CDC25 phosphatases in cancer cells: key players? Good targets? (original) (raw)
Boudolf, V., Inze, D. & De Veylder, L. What if higher plants lack a CDC25 phosphatase? Trends Plant Sci.11, 474–479 (2006). ArticleCASPubMed Google Scholar
Galaktionov, K. & Beach, D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell67, 1181–1194 (1991). ArticleCASPubMed Google Scholar
Sadhu, K., Reed, S. I., Richardson, H. & Russell, P. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl Acad. Sci. USA87, 5139–5143 (1990). ArticleCASPubMedPubMed Central Google Scholar
Nagata, A., Igarashi, M., Jinno, S., Suto, K. & Okayama, H. An additional homolog of the fission yeast cdc25 gene occurs in humans and is highly expressed in some cancer cells. The new Biologist3, 959–968 (1991). This was the first study reporting the existence of multiple human homologues of the yeastcdc25+ gene and also the first report of CDC25 overexpression in cancer cell lines. CASPubMed Google Scholar
Izumi, T. & Maller, J. L. Elimination of cdc2 phosphorylation sites in the cdc25 phosphatase blocks initiation of M-phase. Mol. Cell Biol.4, 1337–1350 (1993). ArticleCAS Google Scholar
Okazaki, K. et al. Isolation of a cDNA encoding the xenopus homologue of mammalian Cdc25A that can induce meiotic maturation of oocytes. Gene178, 111–114 (1996). ArticleCASPubMed Google Scholar
Benazeraf, B. et al. Identification of an unexpected link between the Shh pathway and a G2/M regulator, the phosphatase CDC25B. Dev. Biol.294, 133–147 (2006). ArticleCASPubMed Google Scholar
Wegener, S., Hampe, W., Herrmann, D. & Schaller, H. C. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell Biol.79, 810–815. (2000). ArticleCASPubMed Google Scholar
Baldin, V., Cans, C., Superti-Furga, G. & Ducommun, B. Alternative splicing of the human CDC25B tyrosine phoshatase. Possible implications for growth control? Oncogene14, 2485–2495 (1997). The first report that multiple CDC25B variants derive from a single mRNA by alternative splicing events. ArticleCASPubMed Google Scholar
Forrest, A. R. et al. Multiple splicing variants of cdc25B regulate G2/M progression. Biochem. Biophys. Res. Commun.260, 510–515 (1999). ArticleCASPubMed Google Scholar
Bureik, M. et al. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. Int. J. Oncol.17, 1251–1258. (2000). CASPubMed Google Scholar
Russell, P. & Nurse, P. cdc25+ functions as an inducer in the mitotic control of fission yeast. Cell45, 145–153 (1986). ArticleCASPubMed Google Scholar
Malumbres, M. & Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci.30, 630–641 (2005). ArticleCASPubMed Google Scholar
Kaldis, P. The cdk-activating kinase (CAK): from yeast to mammals. Cell Mol. Life Sci.55, 284–296 (1999). ArticleCASPubMed Google Scholar
Kristjansdottir, K. & Rudolph, J. Cdc25 phosphatases and cancer. Chem. Biol.11, 1043–1051 (2004). A comprehensive review on the different methods used to detect CDC25 overexpression in human cancer. ArticleCASPubMed Google Scholar
Blomberg, I. & Hoffmann, I. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell Biol.19, 6183–6194 (1999). ArticleCASPubMedPubMed Central Google Scholar
Hoffman, I., Draetta, I. & Karsenti, G. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J.13, 4302–4310 (1994). Article Google Scholar
Molinari, M., Mercurio, C., Dominguez, J., Goubin, F. & Draetta, G. F. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep.1, 71–79. (2000). ArticleCASPubMedPubMed Central Google Scholar
Zhao, H., Watkins, J. L. & Piwnica-Worms, H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl Acad. Sci. USA99, 14795–14800 (2002). ArticleCASPubMedPubMed Central Google Scholar
Lindqvist, A., Kallstrom, H., Lundgren, A., Barsoum, E. & Rosenthal, C. K. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J. Cell Biol.171, 35–45 (2005). An important study exploring the relative roles of CDC25A and CDC25B in inducing mitotic onset. The authors show that CDC25B is required for the initial activation of CDK1–cyclin B at the centrosomes, whereas CDC25A is involved in chromatin condensation. ArticleCASPubMedPubMed Central Google Scholar
Mailand, N. et al. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J.21, 5911–5920 (2002). ArticleCASPubMedPubMed Central Google Scholar
Boutros, R., Dozier, C. & Ducommun, B. The when and wheres of CDC25 phosphatases. Curr. Opin. Cell Biol.18, 185–191 (2006). A detailed review of the complex mechanisms that regulate CDC25 activities throughout the cell cycle. ArticleCASPubMed Google Scholar
Millar, J. et al. p55 cdc25 is a nuclear phosphoprotein required for the initiation of mitosis in human cells. Proc. Natl Acad. Sci. USA88, 10500–10504 (1991). ArticleCASPubMedPubMed Central Google Scholar
Lammer, C. et al. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J. Cell Sci.111, 2445–2453 (1998). CASPubMed Google Scholar
Gabrielli, B. G. et al. Cytoplasmic accumulation of CDC25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J. Cell Sci.109, 1081–1093 (1996). The first demonstration of a link between cytoplasmic CDC25B accumulation and centrosomal events that occur during the G2–M transition. CASPubMed Google Scholar
De Souza, C. P., Ellem, K. A. & Gabrielli, B. G. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp. Cell Res.257, 11–21 (2000). ArticleCASPubMed Google Scholar
Gabrielli, B. G., Clarck, J. M., McCormack, A. & Ellem, K. A. O. Hyperphosphorylation of the N-terminal domain of cdc25 regulates activity toward cyclinB1/cdc2 but not cyclin A/cdk2. J. Biol. Chem.272, 28607–28614 (1997). ArticleCASPubMed Google Scholar
Turowski, P. et al. Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol. Biol. Cell14, 2984–2998 (2003). ArticleCASPubMedPubMed Central Google Scholar
Garner-Hamrick, P. A. & Fischer, C. Antisense phosphoorthioate oligonucleotides specifically down-regulate cdc25B causing S-phase delay and persitent antiproliferative effects. Int. J. Cancer76, 720–728 (1998). ArticleCASPubMed Google Scholar
Ferguson, A. M., White, L. S., Donovan, P. J. & Piwnica-Worms, H. Normal cell cycle and checkpoint responses in mice and cells lacking Cdc25B and Cdc25C protein phosphatases. Mol. Cell Biol.25, 2853–2860 (2005). An important study in which the authors challenge the idea that all three CDC25 isoforms are required for normal cell-cycle progression, by successfully generating mice that lack both CDC25B and CDC25C without any obvious defects in cell-cycle function or checkpoint responses. ArticleCASPubMedPubMed Central Google Scholar
Lincoln, A. J. et al. Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation. Nature Genet.30, 446–449 (2002). An interesting study showing thatCdc25b−/−female mice are sterile because of permanent meiotic arrest, resulting from lack of maturation promoting factor (MPF; CDK1-cyclinB1 complex) activity. ArticleCASPubMed Google Scholar
Karlsson-Rosenthal, C. & Millar, J. B. Cdc25: mechanisms of checkpoint inhibition and recovery. Trends Cell Biol.16, 285–292 (2006). ArticleCASPubMed Google Scholar
Cazales, M. et al. CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage. Cell Cycle4, 1233–1238 (2005). ArticleCASPubMed Google Scholar
Dutertre, S. et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2/M transition. J. Cell Sci.117, 2523–2531 (2004). This study demonstrates that phosphorylation by Aurora A is required for CDC25B activity and localization to the centrosomes to initiate mitotic entry. ArticleCASPubMed Google Scholar
Theis-Febvre, N. et al. Protein kinase CK2 regulates CDC25B phosphatase activity. Oncogene22, 220–232 (2003). ArticleCASPubMed Google Scholar
Hoffmann, I., Clarke, P., Marcote, M. J., Karsenti, E. & Draetta, G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self amplification of MPF at mitosis. EMBO J.12, 53–63 (1993). ArticleCASPubMedPubMed Central Google Scholar
Barr, F. A., Sillje, H. H. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nature Rev. Mol. Cell Biol.5, 429–440 (2004). ArticleCAS Google Scholar
Karaiskou, A., Jessus, C., Brassac, T. & Ozon, R. Phosphatase 2A and polo kinase, two antagonistic regulators of cdc25 activation and MPF auto-amplification. J Cell Sci.112, 3747–3756 (1999). CASPubMed Google Scholar
Kumagaï, A. & Dunphy, W. G. Purification and molecular cloning of Plx1, a Cdc25-reg ulatory kinase from Xenopus egg extracts. Science273, 1377–1380 (1996). ArticlePubMed Google Scholar
Qian, Y. W., Erikson, E., Li, C. & Maller, J. L. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol. Cell Biol.18, 4262–4271 (1998). ArticleCASPubMedPubMed Central Google Scholar
Roshak, A. K. et al. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal.12, 405–411 (2000). ArticleCASPubMed Google Scholar
Myer, D. L., Bahassi el, M. & Stambrook, P. J. The Plk3-Cdc25 circuit. Oncogene24, 299–305 (2005). ArticleCASPubMed Google Scholar
Toyoshima-Morimoto, F., Taniguchi, E. & Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep.3, 341–348 (2002). ArticleCASPubMedPubMed Central Google Scholar
Hermeking, H. & Benzinger, A. 14–3-3 proteins in cell cycle regulation. Semin. Cancer Biol.16, 183–192 (2006). ArticleCASPubMed Google Scholar
Davezac, N. et al. Regulation of CDC25B phosphatases subcellular localization. Oncogene19, 2179–2185 (2000). ArticleCASPubMed Google Scholar
Loffler, H. et al. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 1 November 2006 (Epub ahead of print).
Mils, V. et al. Specific interaction between 14. 3. 3 isoforms and the human CDC25B phosphatase. Oncogene19, 1257–1265 (2000). ArticleCASPubMed Google Scholar
Sanchez, Y. et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science277, 1497–1501 (1997). ArticleCASPubMed Google Scholar
Kramer, A. et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nature Cell Biol.6, 884–891 (2004). An interesting study in which CHK1 is reported to localize to the centrosomes of interphase cells, and this pool of CHK1 functions to prevent the premature activation of CDK1–cyclin B. ArticlePubMedCAS Google Scholar
Schmitt, E. et al. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J. Cell Sci.119, 4269–4275 (2006). This study shows that CHK1 phosphorylates CDC25Bin vitroandin vivoduring interphase in the absence of DNA damage, in order to inhibit its mitosis-inducing activity. ArticleCASPubMed Google Scholar
Mirey, G. et al. CDC25B phosphorylated by pEg3 localizes to the centrosome and the spindle poles at mitosis. Cell Cycle4, 806–811 (2005). ArticleCASPubMed Google Scholar
Chen, M. S., Ryan, C. E. & Piwnica-Worms, H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14–3-3 binding. Mol. Cell Biol.23, 7488–7497 (2003). ArticleCASPubMedPubMed Central Google Scholar
Busino, L., Chiesa, M., Draetta, G. F. & Donzelli, M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene23, 2050–2056 (2004). ArticleCASPubMed Google Scholar
Busino, L. et al. Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage. Nature426, 87–91 (2003). ArticleCASPubMed Google Scholar
Donzelli, M. et al. Hierarchical order of phosphorylation events commits Cdc25A to βTrCP-dependent degradation. Cell Cycle3, 469–471 (2004). ArticleCASPubMed Google Scholar
Baldin, V., Cans, C., Knibiehler, M. & Ducommun, B. Phosphorylation of human CDC25B phosphatase by CDK1/cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem.272, 32731–32735 (1997). ArticleCASPubMed Google Scholar
Kanemori, Y., Uto, K. & Sagata, N. β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc. Natl Acad. Sci. USA102, 6279–6284 (2005). ArticleCASPubMedPubMed Central Google Scholar
Hurley, P. J. & Bunz, F. ATM and ATR: components of an integrated circuit. Cell Cycle6, 414–417 (2007). ArticleCASPubMed Google Scholar
Goloudina, A. et al. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle2, 473–478 (2003). ArticleCASPubMed Google Scholar
Xiao, Z. et al. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem.278, 21767–21773 (2003). ArticleCASPubMed Google Scholar
Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science288, 1425–1429 (2000). ArticleCASPubMed Google Scholar
Sorensen, C. S. et al. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell3, 247–258 (2003). ArticleCASPubMed Google Scholar
Matsuoka, S., Huang, M. & Elledge, S. J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science282, 1893–1897 (1998). ArticleCASPubMed Google Scholar
Peng, C. Y. et al. Mitotic and G2 checkpoint control: regulation of 14. 3. 3 protein binding by phosphorylation of CDC25C on Serine-216. Science277, 1501–1505 (1997). ArticleCASPubMed Google Scholar
Yarden, R. I., Pardo-Reoyo, S., Sgagias, M., Cowan, K. H. & Brody, L. C. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nature Genet.30, 285–289 (2002). ArticlePubMed Google Scholar
Raleigh, J. M. & O'Connell, M. J. The G(2) DNA damage checkpoint targets both Wee1 and Cdc25. J. Cell Sci.113, 1727–1736 (2000). CASPubMed Google Scholar
Mikhailov, A., Shinohara, M. & Rieder, C. L. The p38-mediated stress-activated checkpoint. A rapid response system for delaying progression through antephase and entry into mitosis. Cell Cycle4, 57–62 (2005). ArticleCASPubMed Google Scholar
Bulavin, D. V. et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature411, 102–107 (2001). The first study to show the essential role of the p38 kinase in the G2/M checkpoint response to UV radiation, by the phosphorylation of both CDC25B and CDC25C, and by the inhibition of 14-3-3 binding in the case of CDC25B. ArticleCASPubMed Google Scholar
Manke, I. A. et al. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol. Cell17, 37–48 (2005). ArticleCASPubMed Google Scholar
Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2pathway for survival after DNA damage. Cancer Cell11, 175–189 (2007). A very interesting study in which the p38–MAPKAPK2 pathway was shown to function as an alternative checkpoint response to UV in p53-deficient tumour cells, and to be directly activated by DNA-damaging chemotherapeutic agents. ArticleCASPubMedPubMed Central Google Scholar
van Vugt, M. A., Bras, A. & Medema, R. H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell15, 799–811 (2004). In this study, the authors show that although PLK1 is not an essential kinase for mitotic entry in undamaged cells, it becomes indispensable along with CDC25B, for the recovery of G2/M checkpoint arrest after DNA damage. ArticleCASPubMed Google Scholar
Bugler, B. et al. Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Mol. Cancer Ther.5, 1446–1451 (2006). ArticleCASPubMed Google Scholar
Bansal, P. & Lazo, J. S. Induction of Cdc25B regulates cell cycle resumption after genotoxic stress. Cancer Res.67, 3356–3363 (2007). ArticleCASPubMed Google Scholar
Bonin, S., Brunetti, D., Benedetti, E., Gorji, N. & Stanta, G. Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. Virchows Arch.448, 539–544 (2006). ArticleCASPubMed Google Scholar
Ito, Y. et al. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer11, 295–300 (2004). ArticlePubMed Google Scholar
Galaktionov, K. et al. Cdc25 phosphatases as potential human oncogenes. Science269, 1575–1577 (1995). This study was the first report of overexpression of CDC25B in primary tissue samples from human breast cancer, and also the first to associate this overexpression with a higher tumour grade. ArticleCASPubMed Google Scholar
Broggini, M. et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res.20, 4835–4840 (2000). CASPubMed Google Scholar
Ngan, E. S., Hashimoto, Y., Ma, Z. Q., Tsai, M. J. & Tsai, S. Y. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene22, 734–739 (2003). ArticleCASPubMed Google Scholar
Ozen, M. & Ittmann, M. Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. Clin. Cancer Res.11, 4701–4706 (2005). ArticleCASPubMed Google Scholar
Sasaki, H. et al. Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett.173, 187–192 (2001). ArticleCASPubMed Google Scholar
Wu, W., Fan, Y. H., Kemp, B. L., Walsh, G. & Mao, L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res.58, 4082–4085 (1998). CASPubMed Google Scholar
Takemasa, I. et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res.60, 3043–3050 (2000). CASPubMed Google Scholar
Hernandez, S. et al. Differential expression of cdc25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab. Invest.81, 465–473 (2001). ArticleCASPubMed Google Scholar
Talvinen, K. et al. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. Anticancer Res.26, 4745–4751 (2006). CASPubMed Google Scholar
Hu, Y. C., Lam, K. Y., Law, S., Wong, J. & Srivastava, G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin. Cancer Res.7, 2213–2221 (2001). CASPubMed Google Scholar
Miyata, H. et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin. Cancer Res.6, 4859–4865 (2000). CASPubMed Google Scholar
Nishioka, K. et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br. J. Cancer85, 412–421 (2001). ArticleCASPubMedPubMed Central Google Scholar
Kishi, K. et al. Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br. J. Surg.89, 597–603 (2002). ArticleCASPubMed Google Scholar
Sunada, F., Itabashi, M., Ohkura, H. & Okumura, T. p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. World J. Gastroenterol.11, 5696–5700 (2005). ArticleCASPubMedPubMed Central Google Scholar
Ito, Y. et al. Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation. Int. J. Mol. Med.13, 431–435 (2004). CASPubMed Google Scholar
Ito, Y. et al. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett.229, 291–297 (2005). ArticleCASPubMed Google Scholar
Fraczek, M., Wozniak, Z., Ramsey, D. & Krecicki, T. Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis. Eur. Arch. Otorhinolaryngol. 2007 (doi:10-1007/s00405-007-0276-2)
Xu, X. et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin. Cancer Res.9, 1764–1772 (2003). CASPubMed Google Scholar
Kudo, Y. et al. Overexpression of cyclin-dependent kinase activating CDC25B phosphatase in human gastric carcinomas. Jpn J. Cancer Res.88, 947–952 (1997). ArticleCASPubMedPubMed Central Google Scholar
Guo, J. et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene23, 71–81 (2004). ArticlePubMedCAS Google Scholar
Wu, W. et al. Coordinate expression of Cdc25B and ER-α is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res.63, 6195–6199 (2003). CASPubMed Google Scholar
Tsuda, H., Hashiguchi, Y., Inoue, T. & Yamamoto, K. Alteration of G2 cell cycle regulators occurs during carcinogenesis of the endometrium. Oncology65, 159–166 (2003). ArticleCASPubMed Google Scholar
Gasparotto, D. et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res.57, 2366–2368 (1997). CASPubMed Google Scholar
Sato, Y. et al. Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma. Jpn J. Clin. Oncol.31, 428–431 (2001). ArticleCASPubMed Google Scholar
Hernandez, S. et al. CDC25 cell cycle-activating phosphatases and c-myc expresion in human non-hodgkin's lymphomas. Cancer Res.58, 1762–1767 (1998). CASPubMed Google Scholar
Hernandez, S. et al. cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or-C, are over-expressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer89, 148–152 (2000). ArticleCASPubMed Google Scholar
Moreira, G. Jr. et al. Reciprocal CDC25A and p27 expression in B-cell non Hodgkin lymphomas. Diagn. Mol. Pathol.12, 128–132 (2003). Article Google Scholar
Aref, S. et al. c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma. Hematology8, 183–190 (2003). ArticleCASPubMed Google Scholar
Nishioka, K. et al. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br. J. Cancer85, 412–421 (2001). ArticleCASPubMedPubMed Central Google Scholar
Galaktionov, K., Chen, X. C. & Beach, D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature382, 511–517 (1996). ArticleCASPubMed Google Scholar
Ben-Yosef, T., Yanuka, O., Halle, D. & Benvenisty, N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene17, 165–171 (1998). ArticleCASPubMed Google Scholar
Vigo, E. et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol. Cell Biol.19, 6379–6395 (1999). ArticleCASPubMedPubMed Central Google Scholar
Wu, L. et al. E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression. Mol. Cell Biol.20, 7059–7067 (2000). ArticleCASPubMedPubMed Central Google Scholar
Spitkovsky, D., Jansen-Dürr, P., Karsenti, E. & Hoffmann, I. S-phase induction by adenovirus E1A requires activation of cdc25A tyrosine phosphatase. Oncogene12, 2549–2554 (1996). CASPubMed Google Scholar
Loffler, H. et al. Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene22, 8063–8071 (2003). ArticlePubMedCAS Google Scholar
Alderton, G. K. et al. Regulation of mitotic entry by microcephalin and its overlap with ATR signalling. Nature Cell Biol.8, 725–733 (2006). ArticleCASPubMed Google Scholar
Gerstein, A. V. et al. APC/CTNNB1 (β-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer34, 9–16 (2002). ArticleCASPubMed Google Scholar
He, N. et al. Regulation of lung cancer cell growth and invasiveness by β-TRCP. Mol. Carcinog.42, 18–28 (2005). ArticleCASPubMed Google Scholar
Kim, C. J. et al. Somatic mutations of the β-TrCP gene in gastric cancer. Apmis115, 127–133 (2007). ArticleCASPubMed Google Scholar
Bartek, J. & Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell3, 421–429 (2003). ArticleCASPubMed Google Scholar
Kim, S. O. et al. Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors. Cancer101, 1018–1027 (2004). ArticleCASPubMed Google Scholar
Tort, F. et al. Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia19, 112–117 (2005). ArticleCASPubMed Google Scholar
Ray, D. et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res.67, 984–991 (2007). In this study, the authors show that although transgenic expression of CDC25A alone is not sufficient to induce spontaneous tumour growth in mice, CDC25A overexpression generates genomic instability and cooperates with v-Ha-rasor c-neuoncogenes in murine mammary tumorigenesis. ArticleCASPubMed Google Scholar
Ma, Z. Q., Chua, S. S., DeMayo, F. J. & Tsai, S. Y. Induction of mammary gland hyperplasia in transgenic mice over- expressing human cdc25B. Oncogene18, 4564–4576 (1999). ArticleCASPubMed Google Scholar
Yao, Y. et al. Increased susceptibility to carcinogen-induced mammary tumors in MMTV- Cdc25B transgenic mice. Oncogene18, 5159–5166 (1999). References 127 and 128 discuss the effect of CDC25B overexpression in inducing mammary tumour growth. The expression of CDC25B alone promotes proliferation and hyperplasia but requires the presence of a carcinogen to stimulate tumour growth. ArticleCASPubMed Google Scholar
Karlsson, C., Katich, S., Hagting, A., Hoffmann, I. & Pines, J. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J. Cell Biol.146, 573–584 (1999). ArticleCASPubMedPubMed Central Google Scholar
Sexl, V. et al. A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene18, 573–582 (1999). ArticleCASPubMed Google Scholar
Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM-Chk2-CDC25A checkpoint pathway guards against radioresistant DNA synthesis. Nature410, 842–847. (2001). ArticleCASPubMed Google Scholar
Senderowicz, A. M. Targeting cell cycle and apoptosis for the treatment of human malignancies. Curr. Opin. Cell Biol.16, 670–678 (2004). ArticleCASPubMed Google Scholar
Senderowicz, A. M. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog. Drug Res.63, 183–206 (2005). ArticleCASPubMed Google Scholar
Byrd, J. C. et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood109, 399–404 (2007). ArticleCASPubMedPubMed Central Google Scholar
Benson, C. et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer96, 29–37 (2007). ArticleCASPubMed Google Scholar
Prevost, G. P. et al. in Progress in Cell Cycle Research (eds Meijer, L., Jézéquel, A. & Roberge, M.) 225–234 (Life in progress, Roscoff, France, 2003). Google Scholar
Lazo, J. S. et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem.44, 4042–4049 (2001). This study shows how the screening of a compound library coupled with experimental and computational approaches can result in the identification of a potent and specific CDC25 inhibitor. ArticleCASPubMed Google Scholar
Brisson, M. et al. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol. Pharmacol.66, 824–833 (2004). ArticleCASPubMed Google Scholar
Cao, S., Foster, C., Brisson, M., Lazo, J. S. & Kingston, D. G. Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorg. Med. Chem.13, 999–1003 (2005). ArticleCASPubMed Google Scholar
Brezak, M. C. et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Mol. Cancer Ther.4, 1378–1387 (2005). An important study reporting the identification of BN82685, a quinone-based potent CDC25 inhibitor. The fact that this compound inhibits the growth of xenografted human pancreatic tumours when orally administered highlights the value of CDC25 phosphatases as targets for anticancer therapeutics. ArticleCASPubMed Google Scholar
Galcera, M. O., Bigg, D., Prevost, G. & Sidhu, A. CDC25 phosphatases inhibitors. WO 2006/067311 (2006).
Kar, S., Wang, M., Ham, S. W. & Carr, B. I. H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK. Cancer Biol. Ther.5, 1340–1347 (2006). ArticleCASPubMed Google Scholar
Blanchard, J. L., Epstein, D. M., Boisclair, M. D., Rudolph, J. & Pal, K. Dysidiolide and related γ-hydroxy butenolide compounds as inhibitors of the protein tyrosine phosphatase, CDC25. Bioorg. Med. Chem. Lett.9, 2537–2538 (1999). ArticleCASPubMed Google Scholar
Ham, S. W. et al. Naphthoquinone analogs as inactivators of cdc25 phosphatase. Bioorg. Med. Chem. Lett.8, 2507–2510 (1998). ArticleCASPubMed Google Scholar
Wrobel, J. et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2, 3-d]furans and 11-arylbenzo[b]naphtho[2, 3-d]thiophenes. J. Med. Chem.42, 3199–3202 (1999). ArticleCASPubMed Google Scholar
Tamura, K. et al. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res.60, 1317–1325 (2000). CASPubMed Google Scholar
Sohn, J. & Rudolph, J. Catalytic and chemical competence of regulation of cdc25 phosphatase by oxidation/reduction. Biochemistry42, 10060–10070 (2003). ArticleCASPubMed Google Scholar
Kar, S., Wang, M., Ham, S. W. & Carr, B. I. Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK. Biochem. Pharmacol.72, 1217–1227 (2006). ArticleCASPubMed Google Scholar
Mondesert, O. et al. A fission yeast strain expressing human CDC25A phosphatase: a tool for selectivity studies of pharmacological inhibitors of CDC25. Curr. Genet.45, 283–288 (2004). ArticleCASPubMed Google Scholar
Brezak, M. C. et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res.64, 3320–3325 (2004). ArticleCASPubMed Google Scholar
Kar, S., Wang, M., Yao, W., Michejda, C. J. & Carr, B. I. PM-20, a novel inhibitor of Cdc25A, induces extra-cellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol. Cancer Ther.5, 1511–1519 (2006). ArticleCASPubMed Google Scholar
Rudolph, J. Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases. Nature Rev. Cancer7, 202–211 (2007). ArticleCAS Google Scholar
Cazales, M. et al. Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly. Mol. Cancer Ther.6, 318–325 (2007). ArticleCASPubMed Google Scholar
Cheon, H. G., Kim, S. M., Yang, S. D., Ha, J. D. & Choi, J. K. Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur. J. Pharmacol.485, 333–339 (2004). ArticleCASPubMed Google Scholar
Collins, I. & Workman, P. New approaches to molecular cancer therapeutics. Nature Chem. Biol.2, 689–700 (2006). ArticleCAS Google Scholar
Chen, Z. et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer119, 2784–2794 (2006). ArticleCASPubMed Google Scholar
Syljuasen, R. G. et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol. Cell Biol.25, 3553–3562 (2005). ArticleCASPubMedPubMed Central Google Scholar
Matthews, D. J. et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle6, 104–110 (2007). ArticleCASPubMed Google Scholar
Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature444, 687–688 (2006). ArticleCAS Google Scholar
Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res.22, 4673–4680 (1994). ArticleCASPubMedPubMed Central Google Scholar
Retief, J. D. Phylogenetic analysis using PHYLIP. Methods Mol. Biol.132, 243–258 (2000). CASPubMed Google Scholar
van Vugt, M. A., Bras, A. & Medema, R. H. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res.65, 7037–7040 (2005). ArticleCASPubMed Google Scholar
Broggini, M. et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res.20, 4835–4840. (2000). CASPubMed Google Scholar
Kieffer, I., Lorenzo, C., Dozier, C. & Ducommun, B. Differential mitotic degradation of the CDC25B variants. Oncogene 2007 (in the press).